Accordingly, the abundance of stem-like CD8<sup>+</sup> T cells correlate strongly with improved clinical outcomes in patients receiving immune checkpoint inhibitors, adoptive cell therapy, or cancer vaccines across multiple tumor types. Here, CD8A is linked to neoplasm.